Evelyne provides advice and counsel on issues relating to US and international laws and regulations concerning intellectual property. She has experience with patent, trademark, and copyright issues and has worked on complex IP transactions involving patent licensing and IP asset acquisition.
Evelyne has also conducted due diligence evaluations of patents, patent oppositions, patent litigation, and patent interference proceedings, and she has prepared documents for proceedings before the Board of Patent Appeals and Interferences and the Federal Circuit. In addition, she has drafted intellectual property agreements, stock purchase agreements, confidentiality agreements, conflict of interest policy, memoranda of understanding, independent contractor agreements, and patent applications.
Prior to joining Mintz, Evelyne served as an in-house attorney at a start-up company, a senior scientific/legal analyst for an international law firm, and as in-house counsel for KPMG – FIDAL and Fiduciaire de France. She speaks French, Italian, and English.
News & Press
Mintz Advises Underwriters of Viking’s $287.5 Million Public Offering of Common Stock
April 10, 2023
NEW YORK – Mintz represented the syndicate of underwriters led by William Blair & Company, L.L.C., in the public offering of 17,242,000 shares of common stock of Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, at an initial offering price of $14.50 per share.
Recent Insights
NEW YORK – Mintz represented the syndicate of underwriters led by William Blair & Company, L.L.C., in the public offering of 17,242,000 shares of common stock of Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, at an initial offering price of $14.50 per share.
